Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 4/20 | 0.42 |
| ▸ | SLC6A11 | P48066 | 1/20 | 0.42 |
| ▸ | S1PR5 | Q9H228 | 3/20 | 0.40 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.40 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.40 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19289676 | 1.00 | NOTUM (0.42) | NOTUMSLC6A11S1PR5S1PR4S1PR1 | |
| SCHEMBL28613250 | 0.89 | SLC6A11 (0.52) | SLC6A11CYP1A2 | |
| SCHEMBL3839597 | 0.89 | SLC6A11 (0.52) | SLC6A11CYP1A2 | |
| SCHEMBL1519312 | 0.89 | L3MBTL1 (0.40) | NOTUMS1PR1SMN1; SMN2 | |
| SCHEMBL7406444 | 0.83 | S1PR5 (0.41) | NOTUMSLC6A11S1PR5S1PR4S1PR1 | |
| SCHEMBL19897466 | 0.83 | S1PR5 (0.41) | NOTUMSLC6A11S1PR5S1PR4S1PR1 | |
| SCHEMBL19897449 | 0.83 | S1PR5 (0.41) | NOTUMSLC6A11S1PR5S1PR4S1PR1 | |
| SCHEMBL1361559 | 0.79 | S1PR5 (0.43) | NOTUMS1PR5S1PR4S1PR1S1PR3 | |
| SCHEMBL28208619 | 0.79 | SMN1; SMN2 (0.38) | SMN1; SMN2 | |
| SCHEMBL3264345 | 0.76 | CYP1A2 (0.46) | NOTUMS1PR5S1PR4S1PR1S1PR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210163409-A1 | ALTERNATE PROCESSES FOR THE PREPARATION OF PYRROLIDINE DERIVATIVES | Dr Reddys Laboratories Ltd (IN) | 2021-06-03 | — | — | US | disclosed |
| WO-2019016745-A1 | ALTERNATE PROCESSES FOR THE PREPARATION OF PYRROLIDINE DERIVATIVES | DR. REDDY'S LABORATORIES LIMITED (IN) | 2019-01-24 | — | — | WO | disclosed |
| US-7601708-B2 | Bile-acid derived compounds for providing sustained systemic concentrations of drugs after oral administration | XENOPORT, INC. (US) | 2009-10-13 | — | — | US | disclosed |
| US-6992076-B2 | Bile-acid derived compounds for providing sustained systemic concentrations of drugs after oral administration | XENOPORT, INC. (US) | 2006-01-31 | — | — | US | disclosed |
| US-20050272710-A1 | Bile-acid derived compounds for providing sustained systemic concentrations of drugs after oral administration | XENOPORT, INC. (US) | 2005-12-08 | — | — | US | disclosed |
| EP-1343805-A4 | BILE-ACID DERIVED COMPOUNDS FOR PROVIDING SUSTAINED SYSTEMIC CONCENTRATIONS OF DRUGS AFTER ORAL ADMINISTRATION | XENOPORT INC (US) | 2005-07-20 | — | — | EP | disclosed |
| EP-1112253-B1 | BRANCHED ALKYL PYRROLIDINE-3-CARBOXYLIC ACIDS | WARNER LAMBERT CO (US) | 2004-10-20 | — | — | EP | disclosed |
| EP-1343805-A1 | BILE-ACID DERIVED COMPOUNDS FOR PROVIDING SUSTAINED SYSTEMIC CONCENTRATIONS OF DRUGS AFTER ORAL ADMINISTRATION | Xenoport, Inc. (US) | 2003-09-17 | — | — | EP | disclosed |
| US-20020151529-A1 | Bile-acid derived compounds for providing sustained systemic concentrations of drugs after oral administration | XENOPORT, INC. | 2002-10-17 | — | — | US | disclosed |
| WO-2002028881-A1 | BILE-ACID DERIVED COMPOUNDS FOR PROVIDING SUSTAINED SYSTEMIC CONCENTRATIONS OF DRUGS AFTER ORAL ADMINISTRATION | XENOPORT, INC. (US) | 2002-04-11 | — | — | WO | disclosed |
| EP-1112253-A1 | BRANCHED ALKYL PYRROLIDINE-3-CARBOXYLIC ACIDS | WARNER-LAMBERT COMPANY (US) | 2001-07-04 | — | — | EP | disclosed |
| EP-1112253-A1 | BRANCHED ALKYL PYRROLIDINE-3-CARBOXYLIC ACIDS | WARNER-LAMBERT COMPANY (US) | 2001-07-04 | — | — | EP | disclosed |
| US-6245801-B1 | ANTIEPILEPIC AGENTS; BRAIN DISORDERS; PSYCHOLOGICLA DISORDERS | WARNER-LAMBERT COMPANY | 2001-06-12 | — | — | US | disclosed |
| WO-2000015611-A1 | BRANCHED ALKYL PYRROLIDINE-3-CARBOXYLIC ACIDS | WARNER-LAMBERT COMPANY (US) | 2000-03-23 | — | — | WO | disclosed |
| WO-2000015611-A1 | BRANCHED ALKYL PYRROLIDINE-3-CARBOXYLIC ACIDS | WARNER-LAMBERT COMPANY (US) | 2000-03-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210163409-A1 | ALTERNATE PROCESSES FOR THE PREPARATION OF PYRROLIDINE DERIVATIVES | PRKD1, JAK1, JAK3 | NOTUM 1228/4885SLC6A11 3989/4885S1PR5 841/4885 |
| US-20020151529-A1 | Bile-acid derived compounds for providing sustained systemic concentrations of drugs after oral administration | SLC10A2, SLC10A1, ABCB11 | NOTUM 1246/4885SLC6A11 7/4885S1PR5 667/4885 |
| US-20050272710-A1 | Bile-acid derived compounds for providing sustained systemic concentrations of drugs after oral administration | SLC10A2, SLC10A1, ABCB11 | NOTUM 1246/4885SLC6A11 7/4885S1PR5 667/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.